Experimental cell therapy aims to unlock transplants for Hard-to-Match patients
NCT ID NCT07350837
Summary
This early-phase study is testing a new cell therapy called AZD0120 in adults with end-stage kidney disease who are waiting for a transplant but have high levels of antibodies that make finding a compatible donor very difficult. The goal is to see if this therapy can safely reduce those antibodies, a process called desensitization, to help patients become eligible for a transplant. The study will enroll a small group of participants to first check the treatment's safety and how it works in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGHLY SENSITIZED PATIENTS AWAITING KIDNEY TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Tongji Medical Collage of Huazhong University of Science & Technology
Wuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.